Back to News
Nov 17, 2025 12:00 PM

Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control

Newly installed Chairperson Lars Rebien Sorensen signaled a rapid shift in governance and strategic direction at Novo Nordisk A/S (NYSE:NVO), saying he intends to strengthen the board's pharmaceutical and over-the-counter expertise while easing concerns about the sweeping power now held by the Novo Nordisk Foundation.

NVO is trading near recent lows. Review the technical setup here

On Friday, Novo Nordisk held its Extraordinary General Meeting, which was convened to elect new members of the Board of Directors.

At the Extraordinary General Meeting, Helge Lund (chair), Henrik Poulsen (vice chair), and the Board members Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law, and Martin Mackay stepped down from the Board of Directors.

Also Read: Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch

Governance Overhaul Sparks Controversy Among Shareholders

Lars Rebien Sørensen was elected as the chair, and Cees de Jong as vice ...